GD Lifescience: what changed
Two fiscal years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
GD Lifescience
Largest movements
- Cash +€430,254
up €430,254 (+223.2%), from €192,744 to €622,998
mainly Net result for the year (+€504,187) and Receivables within one year (+€294,191)
- Receivables within one year -€294,191
down €294,191 (-93.9%), from €313,247 to €19,056
of which Trade receivables: -€233,870
- Other debts +€188,587
up €188,587, from €0 to €188,587
- Trade debts -€92,159
down €92,159 (-94.9%), from €97,161 to €5,002
- Tax, wage and social debts +€34,312
up €34,312 (+19.0%), from €180,655 to €214,967
- Gross operating margin +€323,453
up €323,453 (+84.5%), from €382,695 to €706,148
- Taxes +€85,775
up €85,775 (+93.9%), from €91,395 to €177,170
- Financial charges +€8,309
up €8,309 (+97.8%), from €8,499 to €16,809
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Cash bridge derived
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €803,775 | €935,202 | +€131,427 | +16.4% |
| Fixed assets | 21/28 | €177,318 | €172,682 | -€4,636 | -2.6% |
| Tangible fixed assets | 22/27 | €8,884 | €4,248 | -€4,636 | -52.2% |
| Plant, machinery and equipment | 23 | €8,884 | - | -€8,884 | |
| Furniture and vehicles | 24 | - | €4,248 | +€4,248 | |
| Financial fixed assets | 28 | €168,434 | €168,434 | = | 0.0% |
| Current assets | 29/58 | €626,457 | €762,521 | +€136,063 | +21.7% |
| Amounts receivable after more than one year | 29 | €113,406 | €113,406 | = | 0.0% |
| Other amounts receivable | 291 | €113,406 | €113,406 | = | 0.0% |
| Amounts receivable within one year | 40/41 | €313,247 | €19,056 | -€294,191 | -93.9% |
| Trade receivables | 40 | €247,526 | €13,656 | -€233,870 | -94.5% |
| Other amounts receivable | 41 | €65,721 | €5,400 | -€60,321 | -91.8% |
| Cash at bank and in hand | 54/58 | €192,744 | €622,998 | +€430,254 | +223.2% |
| Deferred charges and accrued income | 490/1 | €7,060 | €7,060 | = | 0.0% |
| Total equity and liabilities | 10/49 | €803,775 | €935,202 | +€131,427 | +16.4% |
| Equity | 10/15 | €523,572 | €524,259 | +€687 | +0.1% |
| Contributions | 10/11 | €20,000 | €20,000 | = | 0.0% |
| Profit (loss) carried forward | 14 | €503,572 | €504,259 | +€687 | +0.1% |
| Amounts payable | 17/49 | €280,203 | €410,943 | +€130,740 | +46.7% |
| Amounts payable within one year | 42/48 | €277,815 | €408,556 | +€130,740 | +47.1% |
| Trade debts | 44 | €97,161 | €5,002 | -€92,159 | -94.9% |
| Suppliers | 440/4 | €97,161 | €5,002 | -€92,159 | -94.9% |
| Taxes, remuneration and social security | 45 | €180,655 | €214,967 | +€34,312 | +19.0% |
| Taxes | 450/3 | €180,655 | €214,967 | +€34,312 | +19.0% |
| Other amounts payable | 47/48 | €0 | €188,587 | +€188,587 | |
| Accrued charges and deferred income | 492/3 | €2,388 | €2,388 | = | 0.0% |
| Non-recurring operating income | 76A | €0 | - | = | |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €3,111 | €4,636 | +€1,525 | +49.0% |
| Other operating charges | 640/8 | €6,137 | €7,304 | +€1,167 | +19.0% |
| Gross operating margin | 9900 | €382,695 | €706,148 | +€323,453 | +84.5% |
| Operating profit (loss) | 9901 | €373,447 | €694,208 | +€320,761 | +85.9% |
| Financial income | 75/76B | €10,829 | €3,957 | -€6,871 | -63.5% |
| Recurring financial income | 75 | €10,829 | €3,957 | -€6,871 | -63.5% |
| Financial charges | 65/66B | €8,499 | €16,809 | +€8,309 | +97.8% |
| Recurring financial charges | 65 | €8,499 | €16,809 | +€8,309 | +97.8% |
| Profit (loss) for the period before taxes | 9903 | €375,776 | €681,357 | +€305,581 | +81.3% |
| Income taxes | 67/77 | €91,395 | €177,170 | +€85,775 | +93.9% |
| Profit (loss) for the period | 9904 | €284,381 | €504,187 | +€219,806 | +77.3% |
| Profit (loss) for the period to be appropriated | 9905 | €284,381 | €504,187 | +€219,806 | +77.3% |
Source: filed annual accounts (NBB), fiscal years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 3 October 2026 via checked.be.